1. Home
  2. CERO vs ORIS Comparison

CERO vs ORIS Comparison

Compare CERO & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • ORIS
  • Stock Information
  • Founded
  • CERO 2017
  • ORIS 2014
  • Country
  • CERO United States
  • ORIS China
  • Employees
  • CERO N/A
  • ORIS N/A
  • Industry
  • CERO
  • ORIS Farming/Seeds/Milling
  • Sector
  • CERO
  • ORIS Consumer Staples
  • Exchange
  • CERO Nasdaq
  • ORIS Nasdaq
  • Market Cap
  • CERO 5.6M
  • ORIS 5.3M
  • IPO Year
  • CERO N/A
  • ORIS 2024
  • Fundamental
  • Price
  • CERO $5.48
  • ORIS $0.14
  • Analyst Decision
  • CERO Strong Buy
  • ORIS
  • Analyst Count
  • CERO 2
  • ORIS 0
  • Target Price
  • CERO $45.00
  • ORIS N/A
  • AVG Volume (30 Days)
  • CERO 302.9K
  • ORIS 17.3M
  • Earning Date
  • CERO 08-22-2025
  • ORIS 01-01-0001
  • Dividend Yield
  • CERO N/A
  • ORIS N/A
  • EPS Growth
  • CERO N/A
  • ORIS N/A
  • EPS
  • CERO N/A
  • ORIS 0.17
  • Revenue
  • CERO N/A
  • ORIS $15,014,000.00
  • Revenue This Year
  • CERO N/A
  • ORIS N/A
  • Revenue Next Year
  • CERO N/A
  • ORIS N/A
  • P/E Ratio
  • CERO N/A
  • ORIS $0.68
  • Revenue Growth
  • CERO N/A
  • ORIS N/A
  • 52 Week Low
  • CERO $4.27
  • ORIS $0.08
  • 52 Week High
  • CERO $895.40
  • ORIS $56.01
  • Technical
  • Relative Strength Index (RSI)
  • CERO 31.92
  • ORIS 45.14
  • Support Level
  • CERO $4.27
  • ORIS $0.11
  • Resistance Level
  • CERO $7.60
  • ORIS $0.12
  • Average True Range (ATR)
  • CERO 0.54
  • ORIS 0.01
  • MACD
  • CERO -0.22
  • ORIS 0.01
  • Stochastic Oscillator
  • CERO 27.85
  • ORIS 87.15

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

About ORIS Oriental Rise Holdings Limited Ordinary Shares

Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).

Share on Social Networks: